IMKELDI vs ZORTRESS

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 23, 2026·How we rate

Possible drug interaction. IMKELDI and ZORTRESS are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	IMKELDI	ZORTRESS
Rating	New	70/100
Pharmacy pays	~$25.80 /30	~$229.16 /30
Type	RX	RX
Active ingredient	IMATINIB MESYLATE	EVEROLIMUS
Manufacturer	Shorla Oncology	Novartis
Dosage forms	Solution	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Half-life	—	about 30 hours (mean terminal elimination half-life)
Treats	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome	—

imkeldi zortress

Rating

New

70/100

Pharmacy pays

~$25.80 /30

~$229.16 /30

Type

Active ingredient

IMATINIB MESYLATE

EVEROLIMUS

Manufacturer

Shorla Oncology

Novartis

Dosage forms

Solution

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Half-life

—

about 30 hours (mean terminal elimination half-life)

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

—

Frequently asked questions

Which is cheaper, Imkeldi or Zortress?

Imkeldi costs pharmacies less to acquire — about $25.80 vs $229.16 for a 30-count supply, per the CMS NADAC survey. That gap is in the pharmacy's cost of goods, not necessarily in what you pay: your price is set afterwards by your insurer and the pharmacy.

What is the difference between Imkeldi and Zortress?

Imkeldi contains Imatinib Mesylate, while Zortress contains Everolimus — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.